Autoimmune responses in T1DM: Quantitative methods to understand onset, progression, and prevention of disease

Pediatric Diabetes

Volumn 15, Issue 3, 2014, Pages 162-174

  Jaberi Douraki, Majid ^a   Pietropaolo, Massimo ^b  

^a Shalon)   (Canada)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Autoantibodies; Autoimmunity; Avidity; B cells; Markov models; Mathematical models; Predictive algorithms; T cells; T1D; cells

Indexed keywords

AUTOANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; BIOLOGICAL MARKER; INSULIN; PANCREAS ISLET CELL ANTIBODY;

ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; DISEASE COURSE; GENETIC SUSCEPTIBILITY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MATHEMATICAL MODEL; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; T LYMPHOCYTE; ANIMAL; AUTOIMMUNITY; BIOLOGICAL MODEL; CYTOTOXICITY; DIABETES MELLITUS, TYPE 1; IMMUNOLOGY; METABOLISM; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PROGNOSIS; SECRETION (PROCESS);

ANIMALS; AUTOANTIBODIES; AUTOIMMUNITY; BIOLOGICAL MARKERS; CYTOTOXICITY, IMMUNOLOGIC; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; HUMANS; INSULIN; INSULIN-SECRETING CELLS; MODELS, BIOLOGICAL; PROGNOSIS;

EID: 84900442598     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/pedi.12148     Document Type: Article

References (90)

1. Oling V, Marttila J, Ilonen J et al. GAD65- and proinsulin-specific CD4+ T-cells detected by MHC class II tetramers in peripheral blood of type 1 diabetes patients and at-risk subjects. J Autoimmun 2005: 25: 235-243.
2. Reijonen H, Novak EJ, Kochik S et al. Detection of GAD65-specific T-cells by major histocompatibility complex class II tetramers in type 1 diabetic patients and at-risk subjects. Diabetes 2002: 51: 1375-1382.
3. Standifer NE, Ouyang Q, Panagiotopoulos C et al. Identification of novel HLA-A*0201 - restricted epitopes in recent-onset type 1 diabetic subjects and antibody-positive relatives. Diabetes 2006: 55: 3061-3067.
4. Velthuis JH, Unger WW, Abreu JR et al. Simultaneous detection of circulating autoreactive CD8+ T-cells specific for different islet cell-associated epitopes using combinatorial MHC multimers. Diabetes 2010: 59: 1721-1730.
5. Wang J, Tsai S, Han B, Tailor P, Santamaria P. Autoantigen Recognition Is Required for Recruitment of IGRP206-214-Autoreactive CD8+ T Cells but Is Dispensable for Tolerance. J Immunol 2012: 189: 2975-2984.
6. Chentoufi AA, Palumbo M, Polychronakos C. Proinsulin expression by Hassall's corpuscles in the mouse thymus. Diabetes 2004: 53: 354-359.
7. Derbinski J, Schulte A, Kyewski B, Klein L. Promiscuous gene expression in medullary thymic epithelial cells mirrors the peripheral self. Nat Immunol 2001: 2: 1032-1039.
8. Pietropaolo M, Towns R, Eisenbarth GS. Humoral autoimmunity in type 1 diabetes: prediction, significance, and detection of distinct disease subtypes. Cold Spring Harb Perspect Med 2012: 2: a012831. doi: 10.1101/cshperspect.a012831.
9. O'Brien BA, Fieldus WE, Field CJ, Finegood DT. Clearance of apoptotic beta-cells is reduced in neonatal autoimmune diabetes-prone rats. Cell Death Differ 2002: 9: 457-464.
10. O'Brien BA, Huang Y, Geng X, Dutz JP, Finegood DT. Phagocytosis of apoptotic cells by macrophages from NOD mice is reduced. Diabetes 2002: 51: 2481-2488.
11. Beyan H, Buckley LR, Yousaf N, Londei M, Leslie RD. A role for innate immunity in type 1 diabetes? Diabetes Metab Res Rev 2003: 19: 89-100.
12. Cardozo AK, Ortis F, Storling J et al. Cytokines downregulate the sarcoendoplasmic reticulum pump Ca2+ ATPase 2b and deplete endoplasmic reticulum Ca2+, leading to induction of endoplasmic reticulum stress in pancreatic beta-cells. Diabetes 2005: 54: 452-461.
13. Estella E, McKenzie MD, Catterall T et al. Granzyme B-mediated death of pancreatic beta-cells requires the proapoptotic BH3-only molecule bid. Diabetes 2006: 55: 2212-2219.
14. Atkinson MA, Bluestone JA, Eisenbarth GS et al. How does type 1 diabetes develop? The notion of homicide or beta-cell suicide revisited. Diabetes 2011: 60: 1370-1379.
15. O'Sullivan-Murphy B, Urano F. ER stress as a trigger for beta-cell dysfunction and autoimmunity in type 1 diabetes. Diabetes 2012: 61: 780-781.
16. Schnell S. A model of the unfolded protein response: pancreatic beta-cell as a case study. Cell Physiol Biochem 2009: 23: 233-244.
17. Nejentsev S, Howson JM, Walker NM et al. Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A. Nature 2007: 450: 887-892.
18. Morel PA, Dorman JS, Todd JA, McDevitt HO, Trucco M. Aspartic acid at position 57 of the HLA-DQ beta chain protects against type I diabetes: a family study. Proc Natl Acad Sci USA 1988: 85: 8111-8115.
19. Walter U, Toepfer T, Dittmar KE et al. Pancreatic NOD beta cells express MHC class II protein and the frequency of I-A(g7) mRNA-expressing beta cells strongly increases during progression to autoimmune diabetes. Diabetologia 2003: 46: 1106-1114.
20. Amrani A, Verdaguer J, Serra P, Tafuro S, Tan R, Santamaria P. Progression of autoimmune diabetes driven by avidity maturation of a T-cell population. Nature 2000: 406: 739-742.
21. Preda I, McEvoy RC, Lin M et al. Soluble, dimeric HLA DR4-peptide chimeras: an approach for detection and immunoregulation of human type-1 diabetes. Eur J Immunol 2005: 35: 2762-2775.
22. Herold KC, Hagopian W, Auger JA et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002: 346: 1692-1698.
23. Keymeulen B, Vandemeulebroucke E, Ziegler AG et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005: 352: 2598-2608.
24. Bour-Jordan H, Bluestone JA. B cell depletion: a novel therapy for autoimmune diabetes? J Clin Invest 2007: 117: 3642-3645.
25. Clemente-Casares X, Santamaria P. Nanomedicine in autoimmunity. Immunol Lett 2014: 158: 167-174.
26. Tsai S, Shameli A, Yamanouchi J et al. Reversal of autoimmunity by boosting memory-like autoregulatory T cells. Immunity 2010: 32: 568-580.
27. Pietropaolo M, Becker DJ, LaPorte RE et al. Progression to insulin-requiring diabetes in seronegative prediabetic subjects: the role of two HLA-DQ high-risk haplotypes. Diabetologia 2002: 45: 66-76.
28. Verge CF, Gianani R, Kawasaki E et al. Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes 1996: 45: 926-933.
29. Pietropaolo M, Eisenbarth GS. Autoantibodies in human diabetes. Curr Dir Autoimmun 2001: 4: 252-282.
30. Achenbach P, Bonifacio E, Koczwara K, Ziegler AG. Natural history of type 1 diabetes. Diabetes 2005: 54 (Suppl 2): S25-S31.
31. Eisenbarth GS. Update in type 1 diabetes. J Clin Endocrinol Metab 2007: 92: 2403-2407.
32. Maclaren N, Lan M, Coutant R et al. Only multiple autoantibodies to islet cells (ICA), insulin, GAD65, IA-2 and IA-2beta predict immune-mediated (Type 1) diabetes in relatives. J Autoimmun 1999: 12: 279-287.
33. Palosuo T, Virtamo J, Haukka J et al. High antibody levels to prothrombin imply a risk of deep venous thrombosis and pulmonary embolism in middle-aged men - a nested case-control study. Thromb Haemost 1997: 78: 1178-1182.
34. Achenbach P, Hummel M, Thumer L, Boerschmann H, Hofelmann D, Ziegler AG. Characteristics of rapid vs slow progression to type 1 diabetes in multiple islet autoantibody-positive children. Diabetologia 2013: 56: 1615-1622.
35. Ziegler AG, Rewers M, Simell O et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 2013: 309: 2473-2479.
36. Bingley PJ, Christie MR, Bonifacio E et al. Combined analysis of autoantibodies improves prediction of IDDM in islet cell antibody-positive relatives. Diabetes 1994: 43: 1304-1310.
37. Pietropaolo M, Yu S, Libman IM et al. Cytoplasmic islet cell antibodies remain valuable in defining risk of progression to type 1 diabetes in subjects with other islet autoantibodies. Pediatr Diabetes 2005: 6: 184-192.
38. Bollyky J, Sanda S, Greenbaum CJ. Type 1 diabetes mellitus: primary, secondary, and tertiary prevention. Mt Sinai J Med 2008: 75: 385-397.
39. Naik RG, Palmer JP. Preservation of β-cell function in type 1 diabetes. Diabetes Rev 1999: 7: 154-182.
40. Bingley PJ, Gale EA. Incidence of insulin dependent diabetes in England: a study in the Oxford region, 1985-1986. BMJ 1989: 298: 558-560.
41. Eisenbarth GS. Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med 1986: 314: 1360-1368.
42. Kostraba JN, Gay EC, Cai Y et al. Incidence of insulin-dependent diabetes mellitus in Colorado. Epidemiology 1992: 3: 232-238.
43. LaPorte RE, Dorman JS, Tajima N et al. Pittsburgh Insulin-Dependent Diabetes Mellitus Morbidity and Mortality Study: physical activity and diabetic complications. Pediatrics 1986: 78: 1027-1033.
44. Barmeier H, McCulloch DK, Neifing JL et al. Risk for developing type 1 (insulin-dependent) diabetes mellitus and the presence of islet 64K antibodies. Diabetologia 1991: 34: 727-733.
45. Riley WJ, Maclaren NK, Krischer J et al. A prospective study of the development of diabetes in relatives of patients with insulin-dependent diabetes. N Engl J Med 1990: 323: 1167-1172.
46. Maclaren NK. How, when, and why to predict IDDM. Diabetes 1988: 37: 1591-1594.
47. Bingley PJ, Bonifacio E, Gale EA. Can we really predict IDDM? Diabetes 1993: 42: 213-220.
48. Latek RR, Suri A, Petzold SJ et al. Structural basis of peptide binding and presentation by the type I diabetes-associated MHC class II molecule of NOD mice. Immunity 2000: 12: 699-710.
49. Todd JA, Bell JI, McDevitt HO. HLA-DQ beta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature 1987: 329: 599-604.
50. Tisch R, McDevitt H. Insulin-dependent diabetes mellitus. Cell 1996: 85: 291-297.
51. Quartey-Papafio R, Lund T, Chandler P et al. Aspartate at position 57 of nonobese diabetic I-Ag7 beta-chain diminishes the spontaneous incidence of insulin-dependent diabetes mellitus. J Immunol 1995: 154: 5567-5575.
52. Tsai S, Santamaria P. MHC Class II polymorphisms, autoreactive T-cells, and autoimmunity. Front Immunol 2013: 4: 321.
53. Suri A, Walters JJ, Rohrs HW, Gross ML, Unanue ER. First signature of islet beta-cell-derived naturally processed peptides selected by diabetogenic class II MHC molecules. J Immunol 2008: 180: 3849-3856.
54. Stadinski BD, Zhang L, Crawford F, Marrack P, Eisenbarth GS, Kappler JW. Diabetogenic T cells recognize insulin bound to IAg7 in an unexpected, weakly binding register. Proc Natl Acad Sci USA 2010: 107: 10978-10983.
55. Crawford F, Stadinski B, Jin N et al. Specificity and detection of insulin-reactive CD4+ T cells in type 1 diabetes in the nonobese diabetic (NOD) mouse. Proc Natl Acad Sci USA 2011: 108: 16729-16734.
56. Mohan JF, Levisetti MG, Calderon B, Herzog JW, Petzold SJ, Unanue ER. Unique autoreactive T cells recognize insulin peptides generated within the islets of Langerhans in autoimmune diabetes. Nat Immunol 2010: 11: 350-354.
57. Doyle HA, Mamula MJ. Post-translational protein modifications in antigen recognition and autoimmunity. Trends Immunol 2001: 22: 443-449.
58. Anderton SM. Post-translational modifications of self antigens: implications for autoimmunity. Curr Opin Immunol 2004: 16: 753-758.
59. Finegood DT, Scaglia L, Bonner-Weir S. Dynamics of beta-cell mass in the growing rat pancreas. Estimation with a simple mathematical model. Diabetes 1995: 44: 249-256.
60. Trudeau JD, Dutz JP, Arany E, Hill DJ, Fieldus WE, Finegood DT. Neonatal beta-cell apoptosis: a trigger for autoimmune diabetes? Diabetes 2000: 49: 1-7.
61. Nerup J, Mandrup-Poulsen T, Helqvist S et al. On the pathogenesis of IDDM. Diabetologia 1994: 37 (Suppl 2): S82-S89.
62. Nerup J, Mandrup-Poulsen T, Molvig J, Helqvist S, Wogensen L, Egeberg J. Mechanisms of pancreatic beta-cell destruction in type I diabetes. Diabetes Care 1988: 11 (Suppl 1): 16-23.
63. Freiesleben De Blasio B, Bak P, Pociot F, Karlsen AE, Nerup J. Onset of type 1 diabetes: a dynamical instability. Diabetes 1999: 48: 1677-1685.
64. Wang X, He Z, Ghosh S. Investigation of the age-at-onset heterogeneity in type 1 diabetes through mathematical modeling. Math Biosci 2006: 203: 79-99.
65. Marinković T, Sysi-Aho M, Oresic M. Integrated model of metabolism and autoimmune response in beta-cell death and progression to type 1 diabetes. PLoS One 2012: 7: e51909.
66. Topp B, Promislow K, de Vries G, Miura RM, Finegood DT. A model of beta-cell mass, insulin, and glucose kinetics: pathways to diabetes. J Theor Biol 2000: 206: 605-619.
67. Marée AF, Komba M, Finegood DT, Edelstein-Keshet L. A quantitative comparison of rates of phagocytosis and digestion of apoptotic cells by macrophages from normal (BALB/c) and diabetes-prone (NOD) mice. J Appl Physiol 2008: 104: 157-169.
68. Marée AF, Komba M, Dyck C, Labecki M, Finegood DT, Edelstein-Keshet L. Quantifying macrophage defects in type 1 diabetes. J Theor Biol 2005: 233: 533-551.
69. Marée AF, Kublik R, Finegood DT, Edelstein-Keshet L. Modelling the onset of type 1 diabetes: can impaired macrophage phagocytosis make the difference between health and disease? Philos Transact A Math Phys Eng Sci 2006: 364: 1267-1282.
70. Stoffels K, Overbergh L, Giulietti A et al. NOD macrophages produce high levels of inflammatory cytokines upon encounter of apoptotic or necrotic cells. J Autoimmun 2004: 23: 9-15.
71. Khadra A, Santamaria P, Edelstein-Keshet L. The pathogenicity of self-antigen decreases at high levels of autoantigenicity: a computational approach. Int Immunol 2010: 22: 571-582.
72. Yewdell JW, Anton LC, Bennink JR. Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules? J Immunol 1996: 157: 1823-1826.
73. Han B, Serra P, Amrani A et al. Prevention of diabetes by manipulation of anti-IGRP autoimmunity: high efficiency of a low-affinity peptide. Nat Med 2005: 11: 645-652.
74. Aichele P, Kyburz D, Ohashi PS et al. Peptide-induced T-cell tolerance to prevent autoimmune diabetes in a transgenic mouse model. Proc Natl Acad Sci USA 1994: 91: 444-448.
75. Toes RE, Offringa R, Blom RJ, Melief CJ, Kast WM. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc Natl Acad Sci USA 1996: 93: 7855-7860.
76. Marée AF, Santamaria P, Edelstein-Keshet L. Modeling competition among autoreactive CD8+ T cells in autoimmune diabetes: implications for antigen-specific therapy. Int Immunol 2006: 18: 1067-1077.
77. Trudeau JD, Kelly-Smith C, Verchere CB et al. Prediction of spontaneous autoimmune diabetes in NOD mice by quantification of autoreactive T cells in peripheral blood. J Clin Invest 2003: 111: 217-223.
78. Mahaffy JM, Edelstein-Keshet L. Modeling cyclic waves of circulating T cells in autoimmune diabetes. SIAM J Appl Math 2007: 67: 915-937.
79. von Herrath M, Sanda S, Herold K. Type 1 diabetes as a relapsing-remitting disease? Nat Rev Immunol 2007: 7: 988-994.
80. Jaberi-Douraki M, Pietropaolo M, Khadra A. Predictive models of type 1 diabetes progression: understanding T-cell cycles and their implications on autoantibody release. PLoS One 2014: 9: e93326. doi:10.1371/journal.pone.0093326.
81. Tsai S, Clemente-Casares X, Santamaria P. CD8+ Tregs in autoimmunity: learning "self"-control from experience. Cell Mol Life Sci 2011: 68: 3781-3795.
82. Khadra A, Santamaria P, Edelstein-Keshet L. The role of low avidity T cells in the protection against type 1 diabetes: a modeling investigation. J Theor Biol 2009: 256: 126-141.
83. Khadra A, Tsai S, Santamaria P, Edelstein-Keshet L. On how monospecific memory-like autoregulatory CD8+ T cells can blunt diabetogenic autoimmunity: a computational approach. J Immunol 2010: 185: 5962-5972.
84. Sugarman J, Tsai S, Santamaria P, Khadra A. Quantifying the importance of pMHC valency, total pMHC dose and frequency on nanoparticle therapeutic efficacy. Immunol Cell Biol 2013: 91: 350-359.
85. Nelson P, Smith N, Ciupe S, Zou W, Omenn GS, Pietropaolo M. Modeling dynamic changes in type 1 diabetes progression: quantifying beta-cell variation after the appearance of islet-specific autoimmune responses. Math Biosci Eng 2009: 6: 753-778.
86. Brusko TM, Putnam AL, Bluestone JA. Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol Rev 2008: 223: 371-390.
87. Magombedze G, Nduru P, Bhunu CP, Mushayabasa S. Mathematical modelling of immune regulation of type 1 diabetes. Biosystems 2010: 102: 88-98.
88. Mallone R, Kochik SA, Reijonen H et al. Functional avidity directs T-cell fate in autoreactive CD4+ T cells. Blood 2005: 106: 2798-2805.
89. Han B, Serra P, Yamanouchi J et al. Developmental control of CD8 T cell-avidity maturation in autoimmune diabetes. J Clin Invest 2005: 115: 1879-1887.
90. Ajmera I, Swat M, Laibe C, Novere NL, Chelliah V. The impact of mathematical modeling on the understanding of diabetes and related complications. CPT Pharmacometrics Syst Pharmacol 2013: 2: e54.